Patient demographics and transplant characteristics
| . | No. of patients . | % . |
|---|---|---|
| Age at transplant, y | ||
| Median (range) | 48 (18-72) | |
| 18-60 | 211 | 75.9 |
| >60 | 67 | 24.1 |
| Female patients | 122 | 43.9 |
| Disease type | ||
| AML/MDS | 163 | 58.6 |
| Others | 115 | 41.4 |
| ALL | 43 | 15.5 |
| CML/MPNs | 32 | 11.5 |
| Lymphoma | 19 | 6.8 |
| Hodgkin | 11 | 4.0 |
| CLL | 9 | 3.2 |
| Myeloma | 1 | 0.4 |
| HCT-CI score | ||
| Median (range) | 3 (0-9) | |
| ≥3 | 142 | 51.1 |
| DRI | ||
| Low | 27 | 9.7 |
| Intermediate | 117 | 42.1 |
| High | 113 | 40.7 |
| Very high | 21 | 7.6 |
| Donor-recipient sex | ||
| Female donor to male recipient | 54 | 19.4 |
| Other recipient-donor sex combination | 225 | 80.6 |
| Conditioning regimen intensity | ||
| MAC | 144 | 51.8 |
| NMA/RIC | 134 | 48.2 |
| Recipient CMV serostatus | ||
| Reactive | 241 | 86.7 |
| Nonreactive | 36 | 12.9 |
| Nondetermined | 1 | 0.4 |
| Donor-recipient ABO match | ||
| Match | 193 | 69.4 |
| Minor mismatch | 45 | 16.2 |
| Major mismatch | 37 | 13.3 |
| Bidirectional mismatch | 3 | 1.1 |
| Hematopoietic cell source | ||
| PB | 31 | 11.2 |
| BM | 247 | 88.9 |
| NK cell alloreactivity | ||
| No | 201 | 72.3 |
| Yes | 77 | 27.7 |
| HLA-DPB1 match/mismatch | ||
| Match | 55 | 19.8 |
| Permissive mismatch | 155 | 55.8 |
| Nonpermissive mismatch in GVH direction | 39 | 14.0 |
| Nonpermissive mismatch in HVG direction | 29 | 10.4 |
| Presence of DSAs | ||
| Yes | 27 | 9.6 |
| No | 252 | 90.4 |
| Median follow-up (range), mo | 16.9 (0.2-101.9) | |
| Median follow-up of 131 survivors (range), mo | 41.3 (4.7-101.9) |
| . | No. of patients . | % . |
|---|---|---|
| Age at transplant, y | ||
| Median (range) | 48 (18-72) | |
| 18-60 | 211 | 75.9 |
| >60 | 67 | 24.1 |
| Female patients | 122 | 43.9 |
| Disease type | ||
| AML/MDS | 163 | 58.6 |
| Others | 115 | 41.4 |
| ALL | 43 | 15.5 |
| CML/MPNs | 32 | 11.5 |
| Lymphoma | 19 | 6.8 |
| Hodgkin | 11 | 4.0 |
| CLL | 9 | 3.2 |
| Myeloma | 1 | 0.4 |
| HCT-CI score | ||
| Median (range) | 3 (0-9) | |
| ≥3 | 142 | 51.1 |
| DRI | ||
| Low | 27 | 9.7 |
| Intermediate | 117 | 42.1 |
| High | 113 | 40.7 |
| Very high | 21 | 7.6 |
| Donor-recipient sex | ||
| Female donor to male recipient | 54 | 19.4 |
| Other recipient-donor sex combination | 225 | 80.6 |
| Conditioning regimen intensity | ||
| MAC | 144 | 51.8 |
| NMA/RIC | 134 | 48.2 |
| Recipient CMV serostatus | ||
| Reactive | 241 | 86.7 |
| Nonreactive | 36 | 12.9 |
| Nondetermined | 1 | 0.4 |
| Donor-recipient ABO match | ||
| Match | 193 | 69.4 |
| Minor mismatch | 45 | 16.2 |
| Major mismatch | 37 | 13.3 |
| Bidirectional mismatch | 3 | 1.1 |
| Hematopoietic cell source | ||
| PB | 31 | 11.2 |
| BM | 247 | 88.9 |
| NK cell alloreactivity | ||
| No | 201 | 72.3 |
| Yes | 77 | 27.7 |
| HLA-DPB1 match/mismatch | ||
| Match | 55 | 19.8 |
| Permissive mismatch | 155 | 55.8 |
| Nonpermissive mismatch in GVH direction | 39 | 14.0 |
| Nonpermissive mismatch in HVG direction | 29 | 10.4 |
| Presence of DSAs | ||
| Yes | 27 | 9.6 |
| No | 252 | 90.4 |
| Median follow-up (range), mo | 16.9 (0.2-101.9) | |
| Median follow-up of 131 survivors (range), mo | 41.3 (4.7-101.9) |
AML, acute myeloid leukemia; BM, bone marrow; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; NMA, nonmyeloablative; PB, peripheral blood; RIC, reduced-intensity conditioning.